![](https://investorshub.advfn.com/uicon/40536.png?cb=1561902029)
Friday, August 09, 2019 3:51:22 PM
Let’s be frank. It’s small, only 20 patients, and it’s short, only a year. It will be added information to the others who have conducted trials. They also conducted it on younger patients who where already shown to be not responding PED5 inhibitors. These guys were in tough shape. ANYTHING that can help them is an improvement. Good results are a win win because its not another DRUG or SURGERY. IMO, the trail results will be lower than what we have seen recently based on the patients. The ones in the trial who were difficult to begin with logically will have less gain. I think Gershman said 70%. Others like NM who are treating the average Joe and John are having better results because they are treating the average 50 something dude who has slowed up in the sack.
In its simplest form, it’s an injection. Not overly invasive now is it? And it’s NOT umbilical cord stem cells. They are your own, so there no need for FDA oversight and they are obviously safe.... nothing foreign. No crazy reactions etc. The “uncontrolled” stem cell guys we all fear are the ones using other folks stem cells or those derived from fat etc.
Let’s keep it even simpler. No one EVER said it is a 100% fix 100% of the time. It will not work on some, it will not be permanent on some. It is simply another big tool in the doctors toolbox that has great potential in helping folks without DRUGS or SURGERY. Every person helped in any way is a WIN we didn’t have before CaverStem.
Go back at listen to what Dr Narayan said in his video. It’s going to be a big deal. It’s needed.
My guess is that the 100 or so patients treated with CaverStem recently will be part of another bigger, longer trial. It’s a huge work in progress. This is just the beginning my friend.
It’s costing a ton of money to get this company up and running. The notes and warrants are not great. I have not seen one poster here say they are. But the bottom line is that the potential here is still awesome.
If CaverStem, FemCelz and StemSpine work out the kinks and get rolling like I think they will, these super low priced shares will pay off handsomely. It’s not a deal breaker one way or the other if the trial is published this month or not IMHO. They will get it out when they can because doctors want to see it too. And it’s not a deal breaker if there are more small notes. It’s the price of commercialization taking longer than everyone expected.
$CELZ.
Recent CELZ News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 01:00:18 PM
- Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements • PR Newswire (US) • 06/28/2023 12:00:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM